Tag - Corbus Pharmaceuticals

Corbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that its abstracts have been selected for presentations at the American College of Rheumatology (“ACR”) 2017 Annual Meeting being held November 3-8, 2017 in San Diego, California. Read more >>

Corbus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, September 25, 2017 at 8:35 a.m. EDT in New York, NY. Read more >>

Corbus Pharmaceuticals to Host Fireside Chat on Dermatomyositis with Expert Physician and Researcher, Victoria Werth, MD

Corbus Pharmaceuticals Holdings, Inc.(NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it will host a live video webcast (details below) on Tuesday, September 5, 2017 at 12:00 PM ET to discuss dermatomyositis: the disease, its treatment, and its impact on patients’ lives. Read more >>

Corbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research

Corbus Pharmaceuticals Holdings, Inc.(NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that recently analyzed skin biopsy histology data from its Phase 2 study of anabasum for the treatment of diffuse cutaneous systemic sclerosis will be presented at the 15th International Workshop on Scleroderma Research. Read more >>

Inside the small Norwood biotech that’s making investors swoon

The top-performing public biotech in Massachusetts over the past year is located in a nondescript brick building with no signage, located along a stretch of highway in Norwood that is better known for its car dealerships than drug developers.
Investors in Corbus Pharmaceuticals don’t much seem to mind. The 3-year-old company, situated some 25 miles south of Cambridge and the bustling biotech hub of Kendall Square, has seen its stock price increase more than 400 percent since March 2016, putting […]